MeMed to Host Webinar on Best Practice Clinical Use of MeMed BV® for Differentiating Viral from Bacterial Infections on April 28, 2022
April 21, 2022 07:00 ET
|
MeMed
HAIFA, Israel, April 21, 2022 – MeMed (or “the Company”), a leader in the emerging field of advanced host-response technologies, today announces that it will host a webinar entitled “Differentiating...
Marchio CE per due tecnologie pionieristiche di MeMed: il test MeMed BV™ e la piattaforma diagnostica MeMed Key™
June 02, 2020 01:00 ET
|
MeMed
Marchio CE per due tecnologie pionieristiche di MeMed: il test MeMed BV™ e la piattaforma diagnostica MeMed Key™ Una piattaforma strumentale all’avanguardia e un nuovo signature test sulla...
MeMed erhält CE-Kennzeichnung für zwei wegweisende Technologien: den MeMed BV™-Test und die MeMed Key™ Point-of-Need-Plattform
June 02, 2020 01:00 ET
|
MeMed
MeMed erhält CE-Kennzeichnung für zwei wegweisende Technologien: den MeMed BV™-Test und die MeMed Key™ Point-of-Need-Plattform Hochmoderne Instrumentenplattform und neuartiger Signaturtest für...
MeMed a obtenu le marquage CE pour deux de ses technologies novatrices : le test MeMed BV™ et la plateforme MeMed Key™
June 02, 2020 01:00 ET
|
MeMed
MeMed a obtenu le marquage CE pour deux de ses technologies novatrices : le test MeMed BV™ et la plateforme MeMed Key™ Plateforme instrumentale de pointe et un test novateur de la signature...
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform
June 02, 2020 01:00 ET
|
MeMed
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform Cutting-edge instrument platform and a novel host-immune response signature test...